People: OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

3.05USD
28 Jul 2014
Price Change (% chg)

$-0.10 (-3.17%)
Prev Close
$3.15
Open
$3.13
Day's High
$3.15
Day's Low
$3.03
Volume
21,648
Avg. Vol
78,879
52-wk High
$14.25
52-wk Low
$3.02

Search Stocks

Summary

Name Age Since Current Position

Jack Goldstein

66 2010 Independent Chairman of the Board

Scott Cormack

48 2013 President, Chief Executive Officer, Treasurer, Secretary, Director

Cindy Jacobs

56 2008 Executive Vice President, Chief Medical Officer

Susan Wyrick

41

Neil Clendeninn

64 2008 Independent Director

Martin Mattingly

57 2010 Independent Director

H. Stewart Parker

58 2010 Independent Director

David Smith

54 2010 Independent Director

Susan Specht

Director, Investor Relations

Biographies

Name Description

Jack Goldstein

Dr. Jack Goldstein, Ph.D., is Independent Chairman of the Board of Directors of OncoGenex Pharmaceuticals Inc. Dr. Goldstein was President and Chief Operating Officer of Chiron Corporation, a biotechnology company, from November 2004 until its acquisition by Novartis AG in April 2006, prior to which he served as Vice President and President, Chiron Blood Testing Division beginning in 2002. From 2000 to 2002, Dr. Goldstein was General Partner at Windamere Venture Partners, L.L.C., a venture capital fund. From 1997 to 2001, he served as President and Chief Executive Officer of Applied Imaging Corporation, a supplier of instrument systems for prenatal and cancer genetics, where he also served as Chairman of the Board of Directors from 1999 to 2002. Dr. Goldstein currently serves on the Board of Directors of Accuray Incorporated and has served as a director of Orasure Technologies Inc. from May 2006 to May 2011, Illumina, Inc. from June 2006 to May 2010, and Immucor, Inc. from December 2007 to February 2009. Dr. Goldstein holds a B.A. degree in biology from Rider University, and a M.S. degree in immunology and a Ph.D. degree in microbiology from St. John’s University.

Scott Cormack

Mr. Scott Daniel Cormack is President, Chief Executive Officer, Treasurer, Secretary, Director of OncoGenex Pharmaceuticals Inc. He was a co-founder of OncoGenex Technologies Inc., which is our wholly owned subsidiary, and has been its President since May 2000, its Chief Executive Officer since February 2002 and a member of its Board of Directors since May 2000. Mr. Cormack served as interim President, Chief Executive Officer and Chairman of the Board of Directors of Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001. From 1998 to 2001, Mr. Cormack served as Vice President of Milestone Medica Corporation, a seed venture capital firm investing in life sciences opportunities. Mr. Cormack holds a B.S. degree from the University of Alberta

Cindy Jacobs

Dr. Cindy Jacobs, Ph.D., M.D., is Executive Vice President, Chief Medical Officer of OncoGenex Pharmaceuticals, Inc. She had been Executive Vice President and Chief Medical Officer of OncoGenex Technologies Inc. from September 2005 to August 2008. From 1999 to July 2005, Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999, Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs received her Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School.

Susan Wyrick

Ms. Susan Wyrick is no longer Vice President - Finance of OncoGenex Pharmaceuticals, Inc., effective July 11, 2014. Ms. Wyrick has been with our company since June 2012 and previously served as Senior Director, Finance. Ms. Wyrick joined us from Emergent BioSolutions, a biopharmaceutical company, where she was the Director, Site Controller from November 2010 to June 2012, where her duties included managing the accounting and finance department and preparing operating plans and forecasts. From March 2006 to October 2010, Ms. Wyrick served as the Controller at Trubion Pharmaceuticals, Inc., a biopharmaceutical company, which was acquired by Emergent BioSolutions Inc. in October 2010. As Controller, Ms. Wyrick’s responsibilities included managing the accounting department and SEC compliance. Prior to March 2006, Ms. Wyrick served in senior financial positions at publicly-held biotechnology companies. Ms. Wyrick received a B.A. degree in Accounting from the University of Washington and has passed the CPA exam.

Neil Clendeninn

Dr. Neil James Clendeninn, M.D., Ph.D., is Independent Director of OncoGenex Pharmaceuticals Inc. Additionally, he has served as a member of OncoGenex Technologies Inc.’s Board of Directors since September 2004. Dr. Clendeninn served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a biopharmaceutical company and a subsidiary of Pfizer Inc., a pharmaceutical company, from 1993 until his retirement in 2001. Dr. Clendeninn holds a B.A. degree in biology/chemistry from Wesleyan University, and a Ph.D. degree in microbiology/pharmacology and an M.D. degree from New York University.

Martin Mattingly

Dr. Martin A. Mattingly, Ph.D., is Independent Director of OncoGenex Pharmaceuticals, Inc. Since August 2012, Dr. Mattingly has served as a member of Tech Coast Angles. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.

H. Stewart Parker

Ms. H. Stewart Parker is Independent Director of OncoGenex Pharmaceuticals Inc. Ms. Parker has served as the Chief Executive Officer of the Infectious Disease Research Institute, or IDRI, a nonprofit research organization focused on the development of products for the diagnosis, prevention, and treatment of neglected diseases since March 2011. Prior to IDRI, Ms. Parker managed the formation of Targeted Genetics Corporation, a biotechnology company, as a wholly owned subsidiary of Immunex Corporation, a biotechnology company, and served as its President and Chief Executive Officer and as a director from its spinout from Immunex Corporation in 1992 to November 2008. She served in various capacities at Immunex Corporation from August 1981 through December 1991, most recently as Vice President, Corporate Development. She served on the Board of Directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. Ms. Parker has also served as a director of Targeted Genetics Corporation from 1992 to November 2008 and Neose Technologies, Inc. from May 2005 to January 2009. Ms. Parker received her B.A. and M.B.A. degrees from the University of Washington.

David Smith

Mr. David V. Smith is Independent Director of OncoGenex Pharmaceuticals, Inc. Since June 2012 Mr. Smith has served as Chief Operating Officer of IntegenX, Inc., an applied genomics company. From December 2006 to July 2011, Mr. Smith was the Executive Vice President and Chief Financial Officer of Thoratec Corporation, a medical device company. Mr. Smith served as the Vice President and Chief Financial Officer of Chiron Corporation from April 2003 to April 2006, as its Vice President, Finance from February 2002 to April 2003 and as its Vice President and Principal Accounting Officer from February 1999 to February 2002. Mr. Smith earned a B.A degree in economics and history from Willamette University and a M.B.A degree in finance from Golden Gate University. In the past five years, he served as a director and chair of the audit committee of Perlegen Sciences, Inc. from May 2006 to November 2009.

Susan Specht

Basic Compensation

Name Fiscal Year Total

Jack Goldstein

--

Scott Cormack

1,588,610

Cindy Jacobs

1,035,700

Susan Wyrick

431,904

Neil Clendeninn

--

Martin Mattingly

--

H. Stewart Parker

--

David Smith

--

Susan Specht

--
As Of 30 Dec 2013

Options Compensation

Search Stocks